Literature DB >> 26636548

Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1.

Gloria Yiu1, Tue K Rasmussen2, Bahareh Ajami1, David J Haddon1, Alvina D Chu1, Stephanie Tangsombatvisit1, Winston A Haynes1, Vivian Diep1, Larry Steinman3, James Faix1, Paul J Utz3.   

Abstract

OBJECTIVE: Type I interferon (IFN) signaling is a central pathogenic pathway in systemic lupus erythematosus (SLE), and therapeutics targeting type I IFN signaling are in development. Multiple proteins with overlapping functions play a role in IFN signaling, but the signaling events downstream of receptor engagement are unclear. This study was undertaken to investigate the roles of the type I and type II IFN signaling components IFN-α/β/ω receptor 2 (IFNAR-2), IFN regulatory factor 9 (IRF-9), and STAT-1 in a mouse model of SLE.
METHODS: We used immunohistochemical staining and highly multiplexed assays to characterize pathologic changes in histology, autoantibody production, cytokine/chemokine profiles, and STAT phosphorylation in order to investigate the individual roles of IFNAR-2, IRF-9, and STAT-1 in MRL/lpr mice.
RESULTS: We found that STAT-1(-/-) mice, but not IRF-9(-/-) or IFNAR-2(-/-) mice, developed interstitial nephritis characterized by infiltration with retinoic acid receptor-related orphan nuclear receptor γt-positive lymphocytes, macrophages, and eosinophils. Despite pronounced interstitial kidney disease and abnormal kidney function, STAT-1(-/-) mice had decreased proteinuria, glomerulonephritis, and autoantibody production. Phosphospecific flow cytometry revealed shunting of STAT phosphorylation from STAT-1 to STAT-3/4.
CONCLUSION: We describe unique contributions of STAT-1 to pathology in different kidney compartments in a mouse model, and provide potentially novel insight into tubulointerstitial nephritis, a poorly understood complication that predicts end-stage kidney disease in SLE patients.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26636548      PMCID: PMC4848130          DOI: 10.1002/art.39535

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  79 in total

1.  Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases.

Authors:  John C Hall; Livia Casciola-Rosen; Alan E Berger; Efstathia K Kapsogeorgou; Chris Cheadle; Athanasios G Tzioufas; Alan N Baer; Antony Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

2.  Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.

Authors:  Guo-Min Deng; Lena Liu; Frances Rena Bahjat; Polly R Pine; George C Tsokos
Journal:  Arthritis Rheum       Date:  2010-07

3.  The role of Th17/IL-17 on eosinophilic inflammation.

Authors:  Paul M Dias; Gautam Banerjee
Journal:  J Autoimmun       Date:  2012-08-18       Impact factor: 7.094

4.  Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys.

Authors:  José C Crispín; Mohamed Oukka; George Bayliss; Robert A Cohen; Christine A Van Beek; Isaac E Stillman; Vasileios C Kyttaris; Yuang-Taung Juang; George C Tsokos
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

Review 5.  The Th17 family: flexibility follows function.

Authors:  Rajatava Basu; Robin D Hatton; Casey T Weaver
Journal:  Immunol Rev       Date:  2013-03       Impact factor: 12.988

6.  CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis.

Authors:  Oliver M Steinmetz; Jan-Eric Turner; Hans-Joachim Paust; Matthias Lindner; Anett Peters; Kirstin Heiss; Joachim Velden; Helmut Hopfer; Susanne Fehr; Thorsten Krieger; Catherine Meyer-Schwesinger; Tobias N Meyer; Udo Helmchen; Hans-Willi Mittrücker; Rolf A K Stahl; Ulf Panzer
Journal:  J Immunol       Date:  2009-09-04       Impact factor: 5.422

7.  Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice.

Authors:  Roberto Baccala; Rosana Gonzalez-Quintial; Robert D Schreiber; Brian R Lawson; Dwight H Kono; Argyrios N Theofilopoulos
Journal:  J Immunol       Date:  2012-11-21       Impact factor: 5.422

8.  On silico peptide microarrays for high-resolution mapping of antibody epitopes and diverse protein-protein interactions.

Authors:  Jordan V Price; Stephanie Tangsombatvisit; Guangyu Xu; Jiangtao Yu; Dan Levy; Emily C Baechler; Or Gozani; Madoo Varma; Paul J Utz; Chih Long Liu
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

9.  UNC93B1 mediates differential trafficking of endosomal TLRs.

Authors:  Bettina L Lee; Joanne E Moon; Jeffrey H Shu; Lin Yuan; Zachary R Newman; Randy Schekman; Gregory M Barton
Journal:  Elife       Date:  2013-02-19       Impact factor: 8.140

10.  Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis.

Authors:  Paul A Lyons; Eoin F McKinney; Tim F Rayner; Alexander Hatton; Hayley B Woffendin; Maria Koukoulaki; Thomas C Freeman; David R W Jayne; Afzal N Chaudhry; Kenneth G C Smith
Journal:  Ann Rheum Dis       Date:  2009-10-07       Impact factor: 19.103

View more
  7 in total

Review 1.  T cells and autoimmune kidney disease.

Authors:  Abel Suárez-Fueyo; Sean J Bradley; David Klatzmann; George C Tsokos
Journal:  Nat Rev Nephrol       Date:  2017-03-13       Impact factor: 28.314

Review 2.  The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus.

Authors:  Aleš Goropevšek; Marija Holcar; Tadej Avčin
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

Review 3.  Emerging Topical and Systemic JAK Inhibitors in Dermatology.

Authors:  Farzan Solimani; Katharina Meier; Kamran Ghoreschi
Journal:  Front Immunol       Date:  2019-12-03       Impact factor: 7.561

4.  High Interferon Signature Leads to Increased STAT1/3/5 Phosphorylation in PBMCs From SLE Patients by Single Cell Mass Cytometry.

Authors:  Gloria Yiu; Tue Kruse Rasmussen; Brandon L Tsai; Vivian K Diep; David J Haddon; Jennifer Tsoi; Gopika D Miller; Begoña Comin-Anduix; Bent Deleuran; Gay M Crooks; Paul J Utz
Journal:  Front Immunol       Date:  2022-01-28       Impact factor: 7.561

5.  Therapeutic Effects of Tofacitinib on Pristane-Induced Murine Lupus.

Authors:  Jiayi Lin; Yaqin Zhang; Meihua Wang; Yang Zhang; Pin Li; Yingping Cao; Xuwei Yang
Journal:  Arch Rheumatol       Date:  2022-03-03       Impact factor: 1.007

6.  RNAi Silencing of HIF-1α Ameliorates Lupus Development in MRL/lpr Mice.

Authors:  Wei Zhao; Changhao Wu; Lian-Ju Li; Yin-Guang Fan; Hai-Feng Pan; Jin-Hui Tao; Rui-Xue Leng; Dong-Qing Ye
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.657

Review 7.  Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus.

Authors:  Takayuki Katsuyama; George C Tsokos; Vaishali R Moulton
Journal:  Front Immunol       Date:  2018-05-17       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.